Greenbaum B H
Division of Pediatric Hematology/Oncology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson School of Medicine, Camden 08103.
J Clin Oncol. 1991 Oct;9(10):1889-902. doi: 10.1200/JCO.1991.9.10.1889.
Transfusion-associated graft-versus-host disease (TGVHD) has been reported in 131 patients as a complication of supportive treatment with an overall 90% mortality. This study was undertaken to define the historical incidence of TGVHD, its symptomatology, and mortality among affected patients by age, diagnosis, and blood product transfused. Although the use of irradiated blood products (IBPs) virtually eliminates the risk of this highly lethal complication, the use of IBPs appears variable. To ascertain current use of IBPs, questionnaires were sent to 100 pediatric and adult hematologists, oncologists, and bone marrow transplant physicians asking their perceptions about and actual use of IBPs. The results of the questionnaire, information on irradiation effects on cellular blood products, and current recommendations for irradiation of blood products are discussed.
据报道，131例患者发生了输血相关移植物抗宿主病（TGVHD），这是支持性治疗的一种并发症，总体死亡率为90%。本研究旨在确定TGVHD的历史发病率、症状以及不同年龄、诊断和所输血制品的受影响患者的死亡率。尽管使用辐照血液制品（IBP）实际上消除了这种高度致命并发症的风险，但IBP的使用情况似乎各不相同。为确定IBP的当前使用情况，向100名儿科和成人血液学家、肿瘤学家及骨髓移植医生发送了问卷，询问他们对IBP的看法和实际使用情况。文中讨论了问卷结果、辐照对细胞血液制品的影响信息以及当前关于血液制品辐照的建议。
